

2 Contents

3	LIST OF ABBREVIATIONS	9
4	INTRODUCTION	13
4.1	Viral hemorrhagic fevers	19
4.2	Filovirus taxonomy, evolution, and phylogeny.	23
4.3	Biosafety concerns in filovirus research	37
4.4	Biosecurity concerns in filovirus research.	50
5	HISTORY OF FILOVIRAL DISEASE OUTBREAKS	59
5.1	Lake Victoria marburgvirus	64
5.1.1	Germany and Yugoslavia, 1967, and Uganda, 1967 (speculative)	64
5.1.2	South Africa, 1973 (speculative).	68
5.1.3	Rhodesia, 1975.	68
5.1.4	Kenya, 1980.	70
5.1.5	Zimbabwe/South Africa, 1982 (speculative).	70
5.1.6	Togo, 1985 (speculative)	70
5.1.7	Kenya, 1987.	71
5.1.8	Laboratory accident(s), U.S.S.R., 1988	71
5.1.9	Kenya/Sweden, 1990 (speculative)	71
5.1.10	Laboratory accident, U.S.S.R., 1990	72
5.1.11	Kenya/Germany, 1993 (speculative)	72
5.1.12	Zaire, 1987–1996/Democratic Republic of the Congo, 1997–2000.	73
5.1.13	Angola, 2004–2005.	75
5.1.14	Uganda, 2007.	75
5.2	Zaire ebolavirus	75
5.2.1	Zaire, 1976	75
5.2.2	Zaire, 1977	78
5.2.3	Kenya, 1980 (speculative)	79
5.2.4	Zaire, 1980–1985 (speculative).	79
5.2.5	Five independent outbreaks, Gabon, 1994–1995	79
5.2.6	Zaire, 1995	80
5.2.7	Laboratory accident, Russia, 1996.	82
5.2.8	Gabon, 1996.	82
5.2.9	Gabon/South Africa, 1996–1997	82
5.2.10	Eight independent outbreaks in Gabon and Congo (Brazzaville), 2001–2002	83
5.2.11	Congo (Brazzaville) and Gabon, 2002	85
5.2.12	Three independent outbreaks, Congo (Brazzaville), 2002–2003	85
5.2.13	Congo (Brazzaville), 2003–2004.	85

5.2.14	Laboratory accident, U.S.A., 2004 (speculative)	86
5.2.15	Laboratory accident, Russia, 2004.	86
5.2.16	Congo (Brazzaville), 2005	86
5.3	Sudan ebolavirus	86
5.3.1	Sudan, 1976.	86
5.3.2	Laboratory accident, U.K., 1976.	88
5.3.3	Sudan, 1979.	88
5.3.4	Uganda, 2000–2001	88
5.3.5	Sudan, 2004.	90
5.4	Reston ebolavirus	90
5.4.1	The Philippines/U.S.A., 1989–1990	90
5.4.2	The Philippines/Italy, 1992	93
5.4.3	The Philippines/U.S.A., 1996	93
5.5	Côte d’Ivoire ebolavirus.	94
5.5.1	Côte d’Ivoire, 1992 (speculative) and Côte d’Ivoire/Switzerland 1994	94
5.5.2	Liberia and Côte d’Ivoire, 1995 (speculative).	95
5.6	Speculations regarding the occurrence of additional filovirus infections	95
5.7	Conclusions	96
6	CLINICAL PRESENTATION OF FILOVIRAL DISEASE	99
6.1	Lake Victoria marburgvirus infections	99
6.1.1	In humans	99
6.1.2	In nonhuman primates.	104
6.1.3	In guinea pigs	105
6.1.4	In other animals	105
6.2	Zaire ebolavirus infections	106
6.2.1	In humans	106
6.2.2	In nonhuman primates.	110
6.2.3	In guinea pigs	113
6.2.4	In mice	113
6.2.5	In other animals	115
6.3	Sudan ebolavirus infections.	115
6.3.1	In humans	115
6.3.2	In nonhuman primates.	116
6.3.3	In guinea pigs	116
6.3.4	In mice	117
6.4	Reston ebolavirus infections	117
6.5	Côte d’Ivoire ebolavirus infections	118
6.6	Conclusions	118
7	FILOVIRAL DISEASE PATHOLOGY	121
7.1	Marburgvirus disease pathology	121
7.1.1	In humans	121
7.1.2	In nonhuman primates.	123
7.1.3	In guinea pigs, hamsters, and mice	124
7.2	Zaire ebolavirus disease pathology.	128
7.2.1	In humans	128
7.2.2	In nonhuman primates.	130

7.2.3	In guinea pigs	136
7.2.4	In mice	138
7.3	Sudan ebolavirus disease pathology	138
7.4	Reston ebolavirus disease pathology	139
7.5	Côte d'Ivoire ebolavirus disease pathology	140
7.6	Conclusions	140
8	GEOGRAPHIC DISTRIBUTION OF FILOVIRUSES: SEROLOGICAL SURVEYS	143
8.1	Belarus and Ukraine	144
8.2	Benin	144
8.3	Botswana	144
8.4	Burkina Faso	144
8.5	Cameroon	144
8.6	Central African Republic	145
8.7	Congo (Brazzaville)	146
8.8	Côte d'Ivoire	146
8.9	Djibouti	146
8.10	Ethiopia	146
8.11	Gabon	147
8.12	Guinea	147
8.13	Kenya	147
8.14	Liberia	148
8.15	Madagascar	148
8.16	Nigeria	148
8.17	Panama	149
8.18	Philippines	149
8.19	Rhodesia/Zimbabwe	149
8.20	Senegal	149
8.21	Sierra Leone	149
8.22	Sudan	149
8.23	Togo	149
8.24	Uganda	150
8.25	Zaire/Democratic Republic of Congo	150
8.26	Other surveys	150
8.27	Conclusions	151
9	ECOLOGY OF FILOVIRUSES: SEARCH FOR RESERVOIRS	153
9.1	Filoviruses and their association with nonhuman primates	154
9.2	Bats as filovirus reservoirs	159
9.3	Other possible filovirus reservoirs	161
9.4	Conclusions	169
10	CULTIVATION OF FILOVIRUSES	171
10.1	Lake Victoria marburgvirus in cell cultures	171
10.2	Ebolaviruses in cell cultures	172
11	MOLECULAR CHARACTERISTICS OF FILOVIRUSES	175
11.1	Ultrastructure	175
11.2	Filoviral genomes	179

11.3	Filoviral subgenomic mRNAs and their expression products	190
11.3.1	The nucleoprotein gene (<i>NP</i>) and its expression product (nucleoprotein, NP).	191
11.3.2	The <i>VP35</i> gene and its expression product (viral protein 35, VP35)	200
11.3.3	The <i>VP40</i> gene and its expression product (matrix protein, VP40)	201
11.3.4	The ebolavirus <i>GP</i> gene and its primary expression product (secreted glycoprotein, sGP)	205
11.3.5	The ebolaviral <i>GP</i> gene and its secondary expression product (spike protein, GP _{1,2})	208
11.3.6	The ebolaviral <i>GP</i> gene and its tertiary expression product (secondary secreted glycoprotein, ssGP).	215
11.3.7	The marburgviral <i>GP</i> gene and its expression product (spike protein, GP _{1,2})	216
11.3.8	The <i>VP30</i> gene and its expression product (VP30)	219
11.3.9	The <i>VP24</i> gene and its expression product (VP24)	221
11.3.10	The <i>L</i> gene and its expression product (RNA-dependent RNA polymerase, L)	222
11.4	Cellular filovirus lifecycle.	225
11.4.1	Filovirus cell entry	226
11.4.2	Transcription of filoviral genomes.	241
11.4.3	Replication of filoviruses	242
11.4.4	Filovirus maturation and egress.	244
11.5	Pathogenesis of filoviral disease	251
11.6	Conclusions	263
12	LABORATORY DIAGNOSIS OF FILOVIRAL DISEASE	265
12.1	Detection of filoviral RNA	268
12.2	Filovirus isolation	271
12.3	Detection of filoviral antigen.	271
12.3.1	Immunofluorescent assays	271
12.3.2	Antigen-capture ELISA	273
12.3.3	Other assays for filoviral antigen detection.	274
12.4	Detection of specific antibodies to filoviruses	274
12.4.1	Immunofluorescent assays	274
12.4.2	IgM-capture ELISA and IgG ELISA	274
12.4.3	Other assays for antibody detection.	275
12.4.4	Recombinant filoviral antigens for antibody-detection assays	276
12.5	Immunohistochemistry	276
12.6	Electron microscopy	276
12.7	Outlook	277
13	OUTBREAK CONTAINMENT.	279
13.1	Global containment	279
13.2	Outbreak control in Africa	282
13.3	Outbreak control in developed countries.	293
14	INACTIVATION OF FILOVIRUSES AND DISINFECTION PROTOCOLS	297
15	VACCINE DEVELOPMENT.	301
15.1	Inactivated filovirions and filovirus-like particles	304
15.2	DNA candidate vaccines.	313
15.3	Adenovirus candidate vaccines	317

15.4	Venezuelan equine encephalitis virus-based candidate vaccines	319
15.5	Vaccinia virus-based candidate vaccines	325
15.6	Picornavirus-based candidate vaccines	328
15.7	Vesiculovirus-based candidate vaccines.	328
15.8	Respirovirus-based candidate vaccines	329
15.9	Subunit candidate vaccines	332
15.10	Attenuated candidate vaccines	333
15.11	Other candidate vaccines	333
15.12	Conclusions	333
16	TREATMENT OF FILOVIRAL DISEASE	335
16.1	Supportive treatment	335
16.2	Mitigating filoviral disease by modifying host responses.	336
16.2.1	Administration of interferon	336
16.2.2	Modifying cytokine responses.	336
16.2.3	Modulation of coagulation disturbances	337
16.2.4	Traditional treatment	337
16.2.5	Homeopathic approaches	338
16.3	Filovirus-specific antivirals	338
16.3.1	Prevention of filovirus cell entry	338
16.3.2	Terpenes	342
16.3.3	Nucleosides	342
16.3.4	Antisense approaches.	343
16.3.5	Other approaches	345
16.4	Combinatorial treatment.	345
17	APPENDIX: Members of the <i>Filoviridae</i> Study Group, ICTV.	347
18	LIST OF CONTRIBUTORS	349
19	ACKNOWLEDGMENTS	357
20	NOTES ABOUT REFERENCES	359
21	INDEX	361
22	NOTES ABOUT CD-ROM USE	413